Physician profile
Carmen Lopez
NPI 1023549839
$1,848.27
in general payments reported to CMS, 2019-2025
20 companies · $579 in 2025
The $579 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $147 · 2023: $444 · 2024: $678 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $465.45 | 2023-2025 | |
| Janssen Biotech, INC. | $335.90 | 2024-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $221.79 | 2023-2025 | Epclusa |
| Genzyme Corporation | $113.07 | 2023 | |
| Pfizer INC. | $110.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.30 | 2023-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.31 | 2023-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $32.19 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $31.10 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $27.04 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $26.51 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $24.43 | 2023 | Dupixent |
| Novo Nordisk INC | $24.18 | 2024 | |
| Lilly USA, LLC | $18.62 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $17.77 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $17.32 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $16.13 | 2024 | Resolution 360 Clip |
| Amgen INC. | $14.80 | 2025 | Uplizna |
| Ferring Pharmaceuticals INC. | $13.42 | 2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $9.61 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.